Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D017291:Clarithromycin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004269:DNA, Bacterial / Q000235:genetics; D004351:Drug Resistance; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D004415:Dyspepsia / Q000382:microbiology / Q000473:pathology; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005748:Gastric Fundus / Q000382:microbiology / Q000473:pathology; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D005838:Genotype; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000382:microbiology / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000382:microbiology / Q000473:pathology; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D011706:Pyloric Antrum / Q000382:microbiology / Q000473:pathology; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome